• Real Time Chart Real Time Chart
  • Stock Profile Stock Profile
  • Financials As Reported

    • accession Number 0001437749-23-013767
    • accounts Payable Current 6,968,000
    • accounts Receivable Net Current 12,493,000
    • accumulated Depreciation Depletion And Amortization Property Plant And Equipment 3,367,000
    • accumulated Other Comprehensive Income Loss Net Of Tax --45,000
    • allocated Share Based Compensation Expense 2,286,000
    • amendment Flag false
    • assets 112,954,000
    • assets Current 95,973,000
    • cash And Cash Equivalents At Carrying Value 36,540,000
    • cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect --18,866,000
    • cik 1,668,243
    • city Area Code 646
    • common Stock Par Or Stated Value Per Share 0.01
    • common Stock Shares Authorized 100,000,000
    • common Stock Shares Issued 23,440,521
    • common Stock Shares Outstanding 23,400,000
    • comprehensive Income Net Of Tax --30,151,000
    • current Fiscal Year End Date --12-31
    • date Filed 2023-05-11
    • depreciation Depletion And Amortization 200,000
    • document Fiscal Period Focus Q1
    • document Fiscal Year Focus 2,023
    • document Period End Date 2023-03-31
    • document Transition Report false
    • document Type 10-Q
    • earnings Per Share Basic -1.3
    • employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized 14
    • employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 P2Y1M6D
    • entity Address Address Line 1 400 Alexander Park Drive
    • entity Address City Or Town Princeton
    • entity Address Postal Zip Code 8,540
    • entity Address State Or Province NJ
    • entity Central Index Key 1,668,243
    • entity Current Reporting Status Yes
    • entity Emerging Growth Company false
    • entity File Number 001-38079
    • entity Filer Category Non-accelerated Filer
    • entity Incorporation State Country Code L3
    • entity Interactive Data Current Yes
    • entity Name UroGen Pharma Ltd.
    • entity Registrant Name UroGen Pharma Ltd.
    • entity Shell Company false
    • entity Small Business true
    • entity Tax Identification Number 98-1460746
    • gross Profit 14,927,000
    • income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest --30,192,000
    • income Tax Expense Benefit 21,000
    • increase Decrease In Accounts Receivable --211,000
    • increase Decrease In Inventories 1,140,000
    • inventory Net 5,466,000
    • irs Number 0
    • lessee Operating Lease Liability Payments Due 2,676,000
    • lessee Operating Lease Liability Payments Due Next Twelve Months 930,000
    • lessee Operating Lease Liability Payments Due Year Three 53,000
    • lessee Operating Lease Liability Payments Due Year Two 816,000
    • lessee Operating Lease Liability Undiscounted Excess Amount 305,000
    • liabilities 229,508,000
    • liabilities And Stockholders Equity 112,954,000
    • liabilities Current 25,234,000
    • local Phone Number 768-9780
    • long Term Debt Noncurrent 97,941,000
    • net Cash Provided By Used In Financing Activities 671,000
    • net Cash Provided By Used In Investing Activities 6,270,000
    • net Cash Provided By Used In Operating Activities --25,807,000
    • net Income Loss --30,213,000
    • nonoperating Income Expense --15,000
    • operating Income Loss --22,045,000
    • operating Lease Cost 228,000
    • operating Lease Liability 2,371,000
    • operating Lease Liability Noncurrent 1,403,000
    • operating Lease Payments 294,000
    • operating Lease Right Of Use Asset 2,329,000
    • other Assets Noncurrent 3,160,000
    • other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 62,000
    • other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 62,000
    • other Liabilities Current 3,185,000
    • payments To Acquire Property Plant And Equipment 23,000
    • period End 1,680,220,800,000
    • period Start 1,672,531,200,000
    • proceeds From Issuance Of Long Term Debt 0
    • proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 30,469,000
    • property Plant And Equipment Gross 4,470,000
    • property Plant And Equipment Net 1,103,000
    • report Link https://www.sec.gov/Archives/edgar/data/1668243/000143774923013767/urgn20230331_10q_htm.xml
    • research And Development Expense 12,498,000
    • retained Earnings Accumulated Deficit --607,300,000
    • revenue From Contract With Customer Excluding Assessed Tax 17,192,000
    • selling General And Administrative Expense 24,474,000
    • share Based Compensation 2,286,000
    • stockholders Equity --116,554,000
    • trading Symbol URGN
    • unrecognized Tax Benefits 3,000,000
    • update 1970-01-01
    • variable Lease Cost 19,000
    • weighted Average Number Of Shares Outstanding Basic 23,279,951
    • id REPORTED_FINANCIALS
    • key URGN
    • subkey 10-Q
    • date 2023-05-11
    • updated 2023-05-12
  • Symbol Info Symbol Info
  • Symbol Over View Symbol Over View
  • Technical Analysis Technical Analysis

URGN stock fundamentals - financials as reported

Financials As Reported

  • accession Number 0001437749-23-013767
  • accounts Payable Current 6,968,000
  • accounts Receivable Net Current 12,493,000
  • accumulated Depreciation Depletion And Amortization Property Plant And Equipment 3,367,000
  • accumulated Other Comprehensive Income Loss Net Of Tax --45,000
  • allocated Share Based Compensation Expense 2,286,000
  • amendment Flag false
  • assets 112,954,000
  • assets Current 95,973,000
  • cash And Cash Equivalents At Carrying Value 36,540,000
  • cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect --18,866,000
  • cik 1,668,243
  • city Area Code 646
  • common Stock Par Or Stated Value Per Share 0.01
  • common Stock Shares Authorized 100,000,000
  • common Stock Shares Issued 23,440,521
  • common Stock Shares Outstanding 23,400,000
  • comprehensive Income Net Of Tax --30,151,000
  • current Fiscal Year End Date --12-31
  • date Filed 2023-05-11
  • depreciation Depletion And Amortization 200,000
  • document Fiscal Period Focus Q1
  • document Fiscal Year Focus 2,023
  • document Period End Date 2023-03-31
  • document Transition Report false
  • document Type 10-Q
  • earnings Per Share Basic -1.3
  • employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized 14
  • employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 P2Y1M6D
  • entity Address Address Line 1 400 Alexander Park Drive
  • entity Address City Or Town Princeton
  • entity Address Postal Zip Code 8,540
  • entity Address State Or Province NJ
  • entity Central Index Key 1,668,243
  • entity Current Reporting Status Yes
  • entity Emerging Growth Company false
  • entity File Number 001-38079
  • entity Filer Category Non-accelerated Filer
  • entity Incorporation State Country Code L3
  • entity Interactive Data Current Yes
  • entity Name UroGen Pharma Ltd.
  • entity Registrant Name UroGen Pharma Ltd.
  • entity Shell Company false
  • entity Small Business true
  • entity Tax Identification Number 98-1460746
  • gross Profit 14,927,000
  • income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest --30,192,000
  • income Tax Expense Benefit 21,000
  • increase Decrease In Accounts Receivable --211,000
  • increase Decrease In Inventories 1,140,000
  • inventory Net 5,466,000
  • irs Number 0
  • lessee Operating Lease Liability Payments Due 2,676,000
  • lessee Operating Lease Liability Payments Due Next Twelve Months 930,000
  • lessee Operating Lease Liability Payments Due Year Three 53,000
  • lessee Operating Lease Liability Payments Due Year Two 816,000
  • lessee Operating Lease Liability Undiscounted Excess Amount 305,000
  • liabilities 229,508,000
  • liabilities And Stockholders Equity 112,954,000
  • liabilities Current 25,234,000
  • local Phone Number 768-9780
  • long Term Debt Noncurrent 97,941,000
  • net Cash Provided By Used In Financing Activities 671,000
  • net Cash Provided By Used In Investing Activities 6,270,000
  • net Cash Provided By Used In Operating Activities --25,807,000
  • net Income Loss --30,213,000
  • nonoperating Income Expense --15,000
  • operating Income Loss --22,045,000
  • operating Lease Cost 228,000
  • operating Lease Liability 2,371,000
  • operating Lease Liability Noncurrent 1,403,000
  • operating Lease Payments 294,000
  • operating Lease Right Of Use Asset 2,329,000
  • other Assets Noncurrent 3,160,000
  • other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 62,000
  • other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 62,000
  • other Liabilities Current 3,185,000
  • payments To Acquire Property Plant And Equipment 23,000
  • period End 1,680,220,800,000
  • period Start 1,672,531,200,000
  • proceeds From Issuance Of Long Term Debt 0
  • proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 30,469,000
  • property Plant And Equipment Gross 4,470,000
  • property Plant And Equipment Net 1,103,000
  • report Link https://www.sec.gov/Archives/edgar/data/1668243/000143774923013767/urgn20230331_10q_htm.xml
  • research And Development Expense 12,498,000
  • retained Earnings Accumulated Deficit --607,300,000
  • revenue From Contract With Customer Excluding Assessed Tax 17,192,000
  • selling General And Administrative Expense 24,474,000
  • share Based Compensation 2,286,000
  • stockholders Equity --116,554,000
  • trading Symbol URGN
  • unrecognized Tax Benefits 3,000,000
  • update 1970-01-01
  • variable Lease Cost 19,000
  • weighted Average Number Of Shares Outstanding Basic 23,279,951
  • id REPORTED_FINANCIALS
  • key URGN
  • subkey 10-Q
  • date 2023-05-11
  • updated 2023-05-12